Shots:
- Eli Lilly has entered into a definitive agreement to acquire Orna Therapeutics, gaining a broad platform to drive long-term innovation in genetic medicine & in vivo cell engineering
- As per the deal, Lilly will acquire Orna, with Orna’s shareholders receiving up to $2.4B in cash, incl. an upfront & subsequent clinical development milestones payment
- Acquisition will add Orna’s lead program, ORN-252, a clinical-ready, in vivo CD19 CAR-T therapy for B cell-driven autoimmune diseases, along with its circular RNA platform that potentially enables more durable protein expression than current RNA or cell therapies
Ref: Eli Lilly | Image: Orna Therapeutics | Press Release
Related News: Innovent and Eli Lilly Strike ~$8.85B ex-China Collaboration to Accelerate Oncology & Immunology Programs
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
